HER2-positive breast cancer brain metastasis: A new and exciting landscape

Alexandra S. Zimmer | Amanda E. D. Van Swearingen | Carey K. Anders

Abstract

Background: Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti-HER2 therapy following a diagnosis of BrM improves outcomes. Previous preclinical data has helped elucidate HER2 brain tropism, the blood-brain/blood-tumor barrier(s), and the brain tumor microenvironment, all of which can lead to development of novel therapeutic options.

Recent findings: Several anti-HER2 agents are currently available and reviewed here, some of which have recently shown promising effects in BrM patients, specifically. New strategies driven by and focusing on brain metastasis-specific genomics, immunotherapy, and preventive strategies have shown promising results and are under development.

Conclusions: The field of HER2+ breast cancer, particularly for BrM, continues to evolve as new therapeutic strategies show promising results in recent clinical trials. Increasing inclusion of patients with BrM in clinical studies, and a focus on assessing their outcomes both intracranially and extracranially, is changing the landscape for patients with HER2+ CNS metastases by demonstrating the ability of newer agents to improve outcomes.

KEYWORDS
brain metastasis, CNS involvement, HER2-positive breast cancer, T-DM1, trastuzumab, tucatinib

INTRODUCTION

Breast cancer is the most common cancer in women, with 276,480 new cases predicted for the year 2020 in the United States alone. It is also the second most common cause of brain metastases (BrM), with different reports indicating variable 10% to 30% incidence in breast cancer patients. The risk of BrM is subtype specific, with higher incidence among patients with human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer. In the HER2+ subtype of breast cancer, a diagnosis of BrM is common, affecting 25% to 50% of women with advanced disease. While the high incidence of BrM in the HER2-subtype is likely multifactorial, it became more apparent after the arrival of trastuzumab, a HER2-targeting monoclonal antibody (MAb) that improves survival and control of systemic disease but has low central nervous system (CNS) penetrance, and is relatively ineffective at treating BrM.
patients but 30% in autopsy reports. The progressive improvement of systemic treatment of breast cancer led to increased survival as reports emerged of a higher incidence of BrM (28%-48%) in stage IV patients treated with trastuzumab. Aiming to characterize CNS progression in patients with breast cancer in the clinical era of trastuzumab, a multicenter cohort of 1012 patients newly diagnosed with metastatic HER2+ breast cancer was followed in a prospective observational study from 2003 to 2006. Overall, 37% (377/1012) of patients developed CNS metastases, 7.5% (75/1012) at the initial diagnosis of metastatic disease, and 10.5% (106/1012) as the sole, initial site of progression. Trastuzumab was the main anti-HER2 therapy available at the time, and only 5.5% of the patients had received it prior to study entry; however, 93% of patients received it during the follow-up period, and before the first diagnosis of CNS metastases. The median time to development of CNS metastases was 10.8 months, and those patients had a shorter overall survival (OS) than those without CNS involvement (median 26.3 vs 44.6 months). The median survival after first diagnosis of CNS metastases for all patients was 13.0 months. A multivariable analysis showed that systemic treatment with trastuzumab (HR 0.33; 95% CI: 0.25-0.46; P < .001) or chemotherapy (HR 0.64; 95% CI: 0.48-0.85; P = .002) decreased risk of death after CNS metastases, whereas CNS radiotherapy did not (P = .898). This is likely explained by the systemic control of disease.

The pivotal clinical trials that evaluated the adjuvant use of trastuzumab reported an overall low incidence of CNS as the first site of metastatic disease, with mixed results regarding a possible protective effect of trastuzumab. An analysis of CNS relapses as the first event or at any time in the HERA trial data, which had a median follow-up of 4 years, confirmed that the frequency of CNS relapses as the first recurrence event was similar between the group given 1 year of trastuzumab (2%, 37/1703 patients) and the observation group (2%, 32/1698 patients). Nevertheless, a subgroup analysis of 413 patients with available data regarding sites of progression after initial recurrence showed an increased incidence of CNS relapse in patients that did not receive trastuzumab compared to those who had received trastuzumab (57%, 129/227 patients vs 47%, 88/186 patients; P = .06, respectively), again possibly related to improved systemic disease control, resulting in lower rates of CNS seeding.

A series of 123 patients with HER2+ breast cancer brain metastases (BCBrM) treated from 1998 to 2015, was subdivided into three cohorts based on the availability of new standard options of anti-HER2 therapies: 1998 to 2007: trastuzumab; 2008 to 2012: lapatinib; and 2013 to 2015: pertuzumab and T-DM1. While this is a small series with many limitations, as expected, median OS improved over time: 3.56 years for 1998 to 2007 (95% CI, 2.78-6.05), 6.64 years for 2008 to 2012 (95% CI, 4.5-8.58), and 7.55 years for 2013 to 2015 (95% CI, 4.37-9.63) (P = .05). In a similar way, time to BrM diagnosis from initial breast cancer diagnosis increased over time, with a median time to brain recurrence of 2.63 years for 1998 to 2007 (95% CI, 1.34-3.5), 2.61 years for 2008 to 2012 (95% CI, 2.11-4.31), and 3.32 years for 2013 to 2015 (95% CI, 2.22-6.01) (P = .05). Yet, the OS after the CNS metastases diagnosis was 1.51 years (95% CI, 1.24-2.05) for the whole cohort and was not affected by the introduction of novel, systemic therapies (P = .24). However, those who received systemic anti-HER2 therapy after the diagnosis of BrM had improved survival compared to those who did not (2.11 years [95% CI, 1.55-2.60] vs 0.65 years [95% CI, 0.38-1.25], P = .001).

Overall, the magnitude of benefit derived from anti-HER2 systemic therapies in controlling systemic disease with improvements in OS cannot be understated. Moreover, receipt of anti-HER2 therapy has also been associated with improved outcomes following a diagnosis of BrM. In addition, retrospective analyzes have consistently shown better outcomes for patients with HER2+ BrM, especially when also hormone receptor positive, in comparison to those with the triple negative subtype, likely due to the availability of effective, targeted therapies.

## 2 | PRECLINICAL STUDIES

### 2.1 | Mouse models of HER2+ BCBrM

Several methods of modeling BCBrM in mice exist, each with its own benefits and caveats regarding the specific source of cancer cells (human vs mouse), tumor generation method (eg, direct intracranial implantation vs systemic inoculation), and analytical approach (eg, bioluminescence vs histology). As seen in Table 1, careful selection of the specific model must match the specific question(s) being tested, and resulting data must be appropriately interpreted based on the methods used. Some examples of important questions to consider include:

- Is an intact immune system required for this therapeutic intervention? If yes, then a syngeneic model with mouse cancer cells is needed.
- Is this gene/pathway of interest involved in the early metastatic process (eg, intravasation or colonization)? If yes, then direct intracranial implantation is not appropriate.
- Is the ability to monitor/detect individual BrM cells or micrometastases necessary? If yes, then bioluminescence is not appropriate.

In the field of HER2+ breast cancer, the story of HER2 actually started in the brain and has been extensively characterized in animal models. The role of HER2 in cancer was first identified in a rat brain tumor model, and development of the HER2-targeting MAb trastuzumab in animal models has provided a road map for future antibody-based therapeutics (reviewed in Reference 23). Studies of HER2+ BCBrM have utilized the full arsenal of mouse models, ranging from direct implantation of human-derived BC cells into the brains of nude mice to intravenous and intracardiac injection of cells to spontaneous metastasis models. More recently, the field has also been leveraging patient-derived xenografts (PDXs) in immunocompromised mice. Early PDX models derived from tumourspheres of HER2+ primary core needle biopsies demonstrated a capacity for spontaneous metastasis to the brain as well as other organs. However, the increasing...
| Method                  | Benefits                                                                 | Caveats                                                                 | Other considerations                                                                 |
|------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| **Tumor source**       |                                                                          |                                                                          |                                                                                      |
| Human-derived cell line| • Human cancer cell biology                                               | • Immunocompromised mice                                                 | • Lower incidence of extracranial disease in injected xenograft BrM models vs syngeneics |
|                        | • Many established, well-characterized lines                              | • Human cancer in mouse environment                                       |                                                                                      |
|                        | • Can easily differentiate tumor (human) vs environment (mouse) by        | • Cells change with prolonged culture                                    |                                                                                      |
|                        |   sequencing                                                              |                                                                          |                                                                                      |
|                        | • Can genetically alter cells                                             |                                                                          |                                                                                      |
|                        | • Can select for brain trophism                                           |                                                                          |                                                                                      |
| Mouse-derived cell line| • Immunocompetent mice                                                   | • Mouse cancer cell biology                                              | • Syngeneic injected BrM models have shorter survivals vs xenograft models            |
|                        | • Mouse cancer in mouse environment                                       | • Cannot easily differentiate tumor vs environment (both mouse) by        |                                                                                      |
|                        | • Numerous established, well-characterized lines                          |   sequencing                                                              |                                                                                      |
|                        | • Can genetically alter cells                                             | • Cells change with prolonged culture                                    |                                                                                      |
|                        | • Can select for brain trophism                                           |                                                                          |                                                                                      |
| Mouse-derived spontaneous| • Immunocompetent mice                                                   | • Mouse cancer cell biology                                              | • Syngeneic injected BrM models have shorter survivals vs xenograft models            |
|                        | • Mouse cancer in mouse environment                                       | • Difficult to genetically alter the cancer cells                        |                                                                                      |
|                        | • Most faithful modeling of metastatic process                            | • Few models, currently                                                  |                                                                                      |
|                        |                                                                          | • Long latency to BrM                                                    |                                                                                      |
|                        |                                                                          | • Brain trophism harder to enrich                                        |                                                                                      |
|                        |                                                                          | • Requires genetically engineered mice                                    |                                                                                      |
| **Tumor generation**   |                                                                          |                                                                          |                                                                                      |
| Direct intracranial injection | • Established tumor biology                                              | • Does not model early metastatic processes                              |                                                                                      |
|                        | • Quick, high throughput                                                 | • Specialized equipment, skillset needed                                 |                                                                                      |
|                        | • Known, large tumor location                                            | • Induces neuroinflammation                                              |                                                                                      |
|                        | • Reproducible median survival                                           | • Cancer-naive host                                                      |                                                                                      |
| Intracardiac injection | • Reproducible median survival                                           | • Variable BrM rate, especially with nonbrain-trophic cells             |                                                                                      |
|                        | • Minimally invasive surgery                                             | • Systemic circulation of cells leads to extracranial mets              |                                                                                      |
|                        | • Models extravasation, brain colonization and outgrowth                  | • Does not model intravasation                                           |                                                                                      |
|                        | • Average equipment and skillset needed                                  | • Cancer-naive host                                                      |                                                                                      |
| Intracarotid injection | • Reproducible median survival                                           | • Invasive, difficult surgery                                            |                                                                                      |
|                        | • Minimal systemic circulation of injected cancer cells, fewer extracranial mets | • Specialized equipment, skillset needed                                |                                                                                      |
|                        | • Models extravasation, brain colonization and outgrowth                  | • Does not model intravasation                                           |                                                                                      |
| Orthotopic injection    | • Closely models most of the metastatic process                          | • Variable BrM rate, especially with nonbrain-trophic cells             |                                                                                      |
|                        | • Noninvasive implantation                                               | • Long latency to BrM                                                    |                                                                                      |
|                        |                                                                          | • Frequently also develop extracranial tumors                            |                                                                                      |
|                        |                                                                          | • Surgery to resect primary tumor required                                |                                                                                      |
| Spontaneous             | • See above (tumor source)                                               |                                                                          |                                                                                      |
| **Analysis**            |                                                                          |                                                                          |                                                                                      |
| Bioluminescence         | • In vivo and ex vivo                                                     | • Moderate sensitivity                                                  | • Cells must express luciferase                                                       |
|                        | • Noninvasive, real time                                                 | • Moderate spatial resolution                                           | • Cells expressing reporters may activate immune response                             |
|                        | • Quick, high throughput                                                | • No/difficult assessment of microenvironment                          |                                                                                      |
|                        | • Inexpensive                                                            |                                                                          |                                                                                      |
importance of immunotherapies in the clinic has highlighted the need for more immunocompetent models. Syngeneic models of HER2+ BC that spontaneously metastasize to the brain, such as one recently characterized, are poised to become more standard in the field.26

2.2 | Biology of HER2+ BCBrM

Extensive work in HER2+ animal models has provided potential explanations for why this subtype of breast cancer has a predilection for CNS recurrence and subsequent BrM. HER2, as an oncogene itself, may drive brain trophism, as HER2 induces a more mesenchymal state in breast cancer cells, increasing invasiveness and metastatic potential.27 Induced expression of HER2 in experimental models increases the size of BrM from intracardiac injections, and may alter the spatio-temporal growth of BrM within different brain regions toward favoring more posterior areas.28,29

HER2’s ability to increase BrM may be due in part to proposed interactions between HER2 and other spatial factors. Interactions between and signaling from HER2 and its family members, notably the epidermal growth factor receptor (EGFR) and HER3, have been implicated as driving factors in BCBrM (reviewed in Reference 30). BCBrM often over-express HER2 and HER3, and can express mutated EGFR, even relative to primary tumors and other metastases.31-35 The brain microenvironment contains several HER family ligands, including neuregulins, which can cause dimerization and activation of these receptors in brain metastatic cells.31,36 The HER2:HER3 association appears to be particularly important in BCBrM, as it may drive BrM through the release of matrix metalloproteases that can disrupt the blood-brain barrier (BBB).36 Furthermore, the interaction between HER2 and HER3 is enhanced by Src activation and may be a mechanism of resistance to HER2-targeting agents.37 Preclinical models have shown that HER2 can also heterodimerize with the neutrotropin receptor TrkB and be activated by the neutrotropic factor BDNF, suggesting that paracrine signaling increases survival of HER2+ BCBrM.38 Interestingly, estrogen present in premenopausal women may further drive this BDNF/TrkB signaling, as well as the migratory and invasive capacity of breast cancer cells through paracrine signaling from ERα-expressing astrocytes in the brain, further driving the growth of BrM.39,40 Preclinical studies have also shown that HER2, along with EGFR, in BCBrM can alter proliferation by modulating DNA topoisomerase I through nucleolar localization of heparanase (HPSE).41

Additional features of HER2+ BC may contribute to its predilection for BrM. Truncated glioma-associated oncogene homolog 1 (TGLI1) is highly expressed in HER2+ BC and has been shown to increase the incidence of BrM.42 TGLI1 may also contribute to radioresistance by increasing stemness and creating a “metastasis-friendly” microenvironment through activation of astrocytes.42 Fatty acid binding protein 7 (FABP-7) is a lipid binding protein found specifically in the brain. However, FABP-7 is also expressed in BC cells, particularly
in HER2+ cells and in BrM.\textsuperscript{43} FABP7 is thought to induce a more glycolytic, metastatic, and pro-angiogenic state in BC cells, thereby enhancing the survival of HER2+ BC in the foreign brain microenvironment.\textsuperscript{43} Thus, beyond just HER2 expression and its interaction with other receptors, other aspects of HER2+ BC biology likely contribute to the brain metastatic potential of this subtype.

2.3  |  Blood-brain and brain-tumor barriers

The BBB is composed of tight junctions between various brain cells to include most cancer treatments, from crossing into the brain from circulation. However, this barrier is often altered in BrM, including changes in many of the cells that make up the barrier, leading to the concept of a substantially different blood-tumor barrier (BTB).\textsuperscript{44} Seminal papers in different BCBrM mouse models, including HER2-expressing models, demonstrated that the BTB is compromised in the vast majority of experimental BCBrM, enabling increased but heterogeneous, and still often subtoxic, levels of drug uptake by BrM relative to normal brain tissue.\textsuperscript{45}–\textsuperscript{47} Indeed, trastuzumab reaches preclinical brain tumors, but is not as effective at controlling intracranial disease in the clinical setting.\textsuperscript{48} Surprisingly, the distribution of trastuzumab does not appear to be dictated by vascular architecture, or lack thereof, in BrM.\textsuperscript{47} Small molecule HER2 inhibitors do not perform substantially better. Lapatinib does achieve higher levels in intracranial tumors of HER2+ BCBrM mouse models relative to normal brain, but the elevated levels in brain tumors are short-lived (<12 hours), heterogeneous due to differential permeability of the BTB, and below the concentrations reached in extracranial metastases.\textsuperscript{49} This limited exposure is due, in part, to active removal of lapatinib by P-glycoprotein (Pgp) and breast cancer resistance protein (Bcrp) efflux pumps inherent to the BBB.\textsuperscript{50} Historically, efficacy of systemic treatments with most HER2-targeting agents against BrM has been somewhat limited and inconsistent, though newer generation HER2-targeting agents may circumvent these issues.\textsuperscript{51}

Several approaches have been tested in HER2+ BCBrM mouse models to improve access of drugs through the BBB and BTB. Studies have demonstrated the feasibility of using MRI-guided focused ultrasound in HER2+ BCBrM mouse models to disrupt the BBB and thereby increase trastuzumab delivery to BrM.\textsuperscript{52} Focused ultrasound has also been used with microbubbles to increase the accessibility of both chemotherapy and an antibody-drug conjugate (ADC) in a HER2+ BCBrM mouse model.\textsuperscript{53} While these methods hold some promise, improved systemic agents that can better cross the BBB and BTB are needed.

2.4  |  Therapeutic development for HER2+ BCBrM

The development of targeted therapies for both treatment and prevention of BrM in preclinical HER2+ BCBrM animal models has been extensive, ranging from small molecule inhibitors, to antibody-based strategies, to engineered cells under evaluation. Lapatinib, a small molecule inhibitor of EGFR and HER2, was the first HER2-targeting agent characterized in a model of BCBrM.\textsuperscript{54} Animals treated with a higher dose of lapatinib (100 mg/kg) demonstrated significantly fewer large BrM after systemic inoculation of brain-seeking BC cells relative to vehicle-treated controls.\textsuperscript{54} Pazopanib demonstrated prevention potential against HER2+ BC brain micro- and macrometastases in preclinical models by reducing proliferation of tumor cells.\textsuperscript{55} Neratinib treatment completely prevented any BrM, large or small, in a spontaneous HER2+ BC mouse model with a high proclivity for spontaneous BrM.\textsuperscript{56} Newer HER2-targeting agents, such as TAK-285 and Eperitnib (S-222611), display improved efficacy over lapatinib, due in part to achieving higher concentrations in BrM.\textsuperscript{51,56,57}

Beyond traditional small molecule inhibitors, additional novel treatment strategies have been characterized in HER2+ BCBrM models. As discussed above, antibodies targeting HER2, including trastuzumab, have been tested in these models, but with modest efficacy given inconsistent brain penetrance. However, improvements to the antibody-based therapies, such as conjugation with other drugs or with peptides, have also been studied in HER2+ mouse models. An antibody conjugate of trastuzumab and melotransferrin (BT2111) has been shown to reduce the number and size of BrM in a HER2+ mouse model.\textsuperscript{58} An anti-HER2 antibody-peptide conjugate, ANG4043, demonstrated significant efficacy in HER2+ BCBrM mouse models, likely due to its increased BBB permeability through receptor-mediated transcytosis.\textsuperscript{59} A recent report from the Steeg laboratory demonstrated significant reduction of BrM outgrowth in 2 hematogenously generated HER2+ BCBrM models using a novel biparatopic HER2 antibody conjugated to tubulysin.\textsuperscript{60} This reduction in BrM occurred despite low, heterogeneous brain uptake of the antibody conjugate.\textsuperscript{60} Nanoparticle technology has also been explored as a method to increase BrM exposure to HER2-targeting agents. Indeed, albumin nanoparticles demonstrated increased delivery of lapatinib to BrM in animal models, thereby inhibiting the growth of metastases and extending survival.\textsuperscript{61} Combination therapies have also been attempted with nanoparticle delivery, including a chemotherapy plus anti-HER2 antibody combination, which reduced tumor volume in an intracranial HER2+ model.\textsuperscript{62}

There is growing appreciation for the need of combination therapies in HER2+ BCBrM, as HER2-directed therapy alone does not appear to always be sufficient. Activation of the PI3K/mTOR pathway in BCBrM, particularly in HER2+ disease, likely explains the need for combination strategies for HER2+ BCBrM (reviewed in Reference 63). Dual inhibition of PI3K and mTOR in HER2+ BCBrM PDX models improved survival in the absence of a HER2-targeting agent, though some models with high-genomic instability were resistant.\textsuperscript{64} Indeed, trastuzumab required addition of a brain penetrant PI3K/mTOR small molecule inhibitor (GNE-317) or conjugation with a cytotoxic agent (TDM1) to improve survival.\textsuperscript{48} Combination strategies have expanded beyond the PI3K pathway. Partnering Src inhibitors with HER2-targeting lapatinib induced cell cycle arrest and apoptosis, thus reducing the incidence and size of BrM in an intracardiac model.\textsuperscript{37} A triplet strategy combining trastuzumab, lapatinib, and an anti-VEGFR2 antibody drastically improved survival in mouse models of HER2+
BCBrM by decreasing microvessel density in intracranial tumors, thereby increasing necrosis. Recent progress in the field of cell- and viral-based therapeutics has also been applied to HER2+ BCBrM. Human-derived neural stem cells secreting an anti-HER2 antibody, when injected intracranially at the site of tumor implantation, increased survival of mice. Similarly, mesenchymal stromal cells (MSCs) infected with and secreting an engineered virus designed to target HER2 instead of its usual target decreased the incidence of BrM from systemically injected HER2+ BC cells with just one treatment. HER2-CAR T cells delivered intraven-tricularly drastically reduced intracranial HER2+ BC tumors, including multifocal and leptomeningeal disease, thereby increasing survival. Engineered fibroblasts secreting trastuzumab caused tumor growth inhibition and increased survival in a HER2+ BCBrM mouse model when implanted distally (contralaterally) to the tumor. Even viruses alone have shown promise. An engineered adeno-associated virus (AAV) vector, which causes neurons and astrocytes to create an antibody similar to trastuzumab, demonstrated significant efficacy with just a single intrathecal dose on both prevention and treatment of preclinical HER2+ BCBrM. Another adenovirus forcing generation of trastuzumab, when injected contralateral to an implanted intracranial tumor, demonstrated tumor growth inhibition and increased survival. Cell-based and viral-based strategies are rapidly being developed in the HER2 space and have shown significant promise for HER2+ BCBrM.

2.5 Human tissue-based studies

Analyses of patient specimens have further suggested an important role for HER2 in the biology of BrM. HER2 was identified as one of four “brain metastasis selected markers” for CTCs in patients with metastatic BC, where CTCs expressing these markers had increased propensity to spread to the brain. HER2+ BCBrM display increased HER2+ amplification and activation compared to primary tumors. Indeed, one study identified HER2 (and RET) as being gained in patients’ BrM relative to their primaries, and treatment of BrM subcutaneous PDOX models with HER2 and RET inhibitors showed significant growth inhibition. BCBrM also demonstrate increased expression and/or mutation of HER2 family members HER3 and EGFR. Thus, extensive preclinical and correlative work in the field of BCBrM has demonstrated the importance of HER2 and its family members in the biology and potential treatment of BCBrM.

3 CLINICAL MANAGEMENT OF HER2-POSITIVE BrM

The care of patients with HER2+ BCBrM is complex and requires a multidisciplinary team to determine optimal therapy (ie, local or systemic), timing of therapy, and the best management of sequelae of therapy (ie, radiation therapy necrosis) (see algorithm, Figure 1). In addition, as patient symptom burden can be high, incorporation of palliative care early is also recommended as part of the multidisciplinary team, in addition to radiation oncology, medical oncology, and neurosurgery.

3.1 Local therapy

Local therapy modalities, including neurosurgical resection, stereotactic radiosurgery (SRS), and/or whole-brain radiotherapy (WBRT) remain the cornerstone of therapy for BrM. Neurosurgical resection offers survival benefit when associated with adjuvant radiation therapy, more so in patients with good performance status, controlled systemic disease, and a solitary brain lesion. While SRS is preferred...
in cases with a limited number of BrM, the upper limit of number of lesions remains controversial. Finally, for patients with multiple, diffuse BrM, WBRT is the recommended treatment modality, but has fallen out of favor in recent years due to observed negative impacts on longer-term neurocognition.

It is important to highlight that most prospective trials evaluating local treatment of BrM included mainly NSCLC patients, with only a small proportion (~10%-15%) incorporating breast cancer patients.Overall, these trials demonstrated that adding WBRT to initial surgery or SRS decreased intracranial disease recurrence without affecting OS (median 7 to 10 months, \( P = .42 \) to \( P = .93 \)). Conversely, WBRT has been reported to worsen quality of life and neurocognitive function, particularly in patients with prolonged survival. In those cases, neurocognitive decline is progressive and untreatable. Preventive strategies using memantine and hippocampal avoidance have shown improvements in neurocognitive decline.

Retrospective analysis of breast cancer patients treated with local therapy for BrM showed that the subtype affects patterns of failure of BrM after treatment with SRS. Luminal HER2+ (HER2+, HR+) patients had a rate of 36% to 38% distant brain new lesions at 1 year, with a median 18 to 22 months OS, while HER2+ cases (HER2+, HR-) had a rate of 47% to 53% and OS of 11 to 15.4 months. This can help guide discussions clinically, and also begs for systemic therapy agents in the secondary prevention setting to protect against distant brain recurrence after focused radiotherapy in patients with HER2+ BCBrM.

### 3.2 Systemic therapy overview

Systemic therapy for BrM, overall, has shown less efficacy than in systemic, non-CNS locations. Multiple clinical trials have documented few or no responses using agents with known activity in the metastatic setting. In HER2+ BC patients, HER2 targeted agents beyond trastuzumab have been evaluated for their potential therapeutic effect in BrM.

#### 3.2.1 Lapatinib/capecitabine

Lapatinib is a small molecule tyrosine-kinase inhibitor (TKI) of EGFR and HER2, and is able to cross the BBB. As such, it was the first therapy with promising activity in HER2+ BCBrM patients. However, analysis of lapatinib and capecitabine levels in BrM from patients dosed preoperatively for medically needed craniotomies showed concentrations were very heterogeneous. When given as a single agent, lapatinib leads to few responses (2%-6%) and only a small, nonsignificant decrease in the size of BrM lesions. Phase II trials evaluating the combination of lapatinib plus capecitabine in patients with BrM previously treated with WBRT showed an objective response rate of 30%. When the combination was given as first line therapy to 45 patients with low-volume BrM in the LANDSCAPE trial (single arm phase II), an objective CNS responses of 65.9% (measured by volumetric reduction), median time to CNS progression of 5.5 months, and median time to WBRT of 8.5 months were shown. However, this treatment was associated with a 49% grade 3 to 4 toxicity rate, mainly represented by diarrhea, hand-foot syndrome and fatigue. The MA.31 phase II trial randomized 652 patients with HER2+ BC to treatment with either lapatinib plus paclitaxel or trastuzumab plus paclitaxel as first line treatment of metastatic disease. The trastuzumab combination was superior to the lapatinib combination with median progression free survival (PFS) of 9.0 months and 11.3 months, respectively (HR 1.37, \( P = .001 \)). The incidence of BrM as the first site of progression was 28% for trastuzumab and 20% for lapatinib, with no difference in time to progression between the arms. Considering a potential effect in preventing the development of BrM, a phase III trial of lapatinib plus capecitabine vs capecitabine alone in patients with HER2+ advanced BC who were previously treated with an anthracycline, taxane, and trastuzumab was developed. Patients with baseline BrM were excluded, and only four (2%) patients developed symptomatic BrM as an initial site of progression in the combination therapy arm compared to 13 (6%) patients in the monotherapy group (\( P = .045 \)).

#### 3.2.2 Neratinib/capecitabine

Neratinib is a pan-HER TKI that targets and inhibits EGFR/HER1, HER2, and HER4 in an irreversible way. Based on the phase II TBCRC 022 trial results, neratinib received an orphan drug designation for HER2+ BCBrM by the FDA in 2019. In this trial, the combination of neratinib plus capecitabine was evaluated in two cohorts, depending on the previous use of lapatinib. Volumetric BrM response was the primary objective of this clinical trial. In the lapatinib-naive cohort \( (n = 37) \), 18 (49%) patients had partial responses (PR) and 7 (19%) patients had stable disease (SD) for ≥6 cycles (4.2 months), with median PFS 5.5 months and OS 13.3 months. When RANO-BM was applied to evaluate responses, 9 (24%) patients had a PR in that cohort. In the cohort of patients that had received lapatinib in the past \( (n = 12) \), which was closed for slow accrual, 4 (33%) patients had a PR and 3 (25%) patients had SD for ≥6 cycles (4.2 months), with a PFS of 3.1 months and OS of 15.5 months. Per RANO-BM evaluation, 2 (17%) patients had a PR. Notable toxicity was observed in both groups, with grade 2 and 3 toxicity levels reported: 62% diarrhea (despite prophylaxis therapy), 24% nausea, 20% vomiting, and 26% fatigue. Overall, neratinib demonstrated a modest effect in the CNS, mostly short-lived, with non-negligible toxicity.

#### 3.2.3 Tucatinib/trastuzumab/capecitabine

Tucatinib is a TKI that inhibits HER2 in a reversible way. It has shown promising activity in combination with capecitabine and trastuzumab in a phase I trial, which included notable response in BrM. Building on that, the HER2CLIMB phase III trial was developed and results were recently reported. The trial randomized 612 patients with...
HER2+ metastatic BC previously treated with trastuzumab, pertuzumab and T-DM1, to trastuzumab and capcitabine, plus tucatinib or placebo. Patients with BrM were allowed to enroll either without or after local therapy, if indicated for symptom control. Patients with progressive BrM and even untreated, asymptomatic BrM were included. The addition of tucatinib to capcitabine and trastuzumab improved PFS at 1 year (33.1% vs 12.3%, HR 0.54; 95% confidence interval [CI], 0.42 to 0.71; \( P < .001 \)), with corresponding improvements in PFS of 7.8 months and 5.6 months, respectively, for the global patient population. OS at 2 years was improved (44.9% vs 26.6%, HR 0.66; 95% CI, 0.50 to 0.88; \( P = .005 \)) with tucatinib, with median OS of 21.9 months and 17.4 months, respectively.

Specific to patients with BrM, 1-year PFS was 24.9% with addition of tucatinib and 0% in the placebo-combination group (HR 0.48; 95% CI, 0.34 to 0.69; \( P < .001 \)). Median PFS for those with BrM was 7.6 months with tucatinib vs 5.4 months without tucatinib. The exploratory analysis of intracranial outcomes was also reported recently.\(^{102}\) A total of 291 patients with BrM were enrolled in the HER2CLIMB trial, 174 with active BrM, either treated and progressing or untreated, and 117 with treated and stable BrM. The CNS objective response rate in the evaluable subset (55 patients in the tucatinib group and 20 patients in the placebo group) was 47% vs 20%, \( P = .03 \), with a median duration of response of 6.8 months vs 3.0 months, respectively. The median CNS PFS was also improved by tucatinib, with 9.9 months vs 4.2 months, \( P = .00001 \), in all BrM patients; with median 9.5 months vs 4.1 months in patients with active BrM, \( P < .0001 \), and 13.9 months vs 5.6 months in patients with stable BrM, \( P = .002 \). The regimen tucatinib, capcitabine and trastuzumab was approved in April 2020 for adult patients with advanced unresectable or metastatic HER2+ BC, including patients with BrM, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

### 3.2.4 | Pertuzumab

Pertuzumab is a mAb that binds to the extracellular domain II of HER2 and inhibits the dimerization of HER2 with other HER family receptors, especially HER3. In this way, it acts in synergy with trastuzumab. It was demonstrated to prolong OS when offered in combination to trastuzumab and docetaxel as first line treatment for metastatic HER2+ BC in the Cleopatra phase III, randomized, controlled trial.\(^{103}\) The incidence of BrM as the first site of disease progression was evaluated in an exploratory analysis, and found to be similar in the pertuzumab arm and the placebo arm (13.7% and 12.6%).\(^{104}\)

Pertuzumab also showed some benefit when added to chemotherapy and trastuzumab in the adjuvant setting in patients with high-risk HER2+ BC.\(^{105}\) In a recent update, with a median 74.1 months follow-up, the incidence of CNS metastases as invasive disease first recurrence was not different with or without use of adjuvant pertuzumab, 2% in both arms.\(^{106}\)

### 3.2.5 | TDM-1 (trastuzumab emtansine)

T-DM1 is an ADC containing emtansine (DM1), a microtubule-inhibitory agent, linked to trastuzumab. It was the first ADC agent to be approved for treatment of HER2+ BC. Several case reports have described the activity of T-DM1 in CNS metastases.\(^{107,108}\) Phase III trials have shown activity of T-DM1 in HER2+ metastatic disease after previous lines of treatment including trastuzumab and lapatinib, with improvements in both PFS and OS.\(^{109,110}\) T-DM1 is currently the standard therapy for HER2+ BC patients with recurrence or progression of disease after treatment with trastuzumab and pertuzumab. The EMILIA trial randomized advanced HER2+ BC patients, previously treated with trastuzumab and taxanes, to receive either T-DM1 or the combination of lapatinib plus capcitabine.\(^{110}\) Final results showed better PFS (median 9.6 months with T-DM1 vs 6.4 months with lapatinib plus capcitabine; HR 0.65; 95% CI, 0.55 to 0.77; \( P < .001 \)), and OS (30.9 months vs 25.1 months; HR 0.68; 95% CI, 0.55 to 0.85; \( P < .001 \)) with use of T-DM1. In a retrospective exploratory analysis of CNS outcomes as part of the EMILIA trial, the rate of CNS progression was similar between the two arms, with CNS metastases as the first site of relapse in 2% of T-DM1 treated patients and in 0.7% of lapatinib plus capcitabine treated patients, and progression of CNS disease known at baseline in 22.2% and 16%, respectively. Nevertheless, in patients with treated, asymptomatic CNS metastases at baseline, T-DM1 was associated with improved survival when compared to lapatinib plus capcitabine (median 26.8 vs 12.9 months, HR 0.38 \( P = .008 \)). This has been interpreted to be due to excellent control of systemic disease, potentially affecting CNS disease progression and OS.

More recently, in the phase III KATHERINE trial, T-DM1 has been shown to improve invasive disease-free survival (IDFS) in patients with early HER2+ BC that presented with residual invasive disease after neoadjuvant treatment with trastuzumab and taxanes.\(^{112}\) In the interim analysis, with a median follow-up around 40 months, the rate of distant recurrence was 10.5% with T-DM1 and 15.9% with trastuzumab. Interestingly, the rate of CNS recurrence as first IDFS event was 5.9% with T-DM1 and 4.3% with trastuzumab. In a more detailed analysis,\(^{113}\) it was found that the incidence of CNS recurrence after first IDFS event was 0.1% with T-DM1 and 1.1% with trastuzumab, making a total CNS involvement of 6.1% with T-DM1 and 5.4% with trastuzumab. CNS was the only site of recurrence in 4.8% of T-DM1 cases and 2.8% of trastuzumab cases. Moreover, the median time to recurrence in the CNS was 17.5 months with T-DM1 and 11.9 months with trastuzumab. The OS after a CNS event was similar between both treatment groups (12.5 months for T-DM1 and 14.3 months for trastuzumab, unstratified HR [95% CI] = 1.07 [0.60-1.91]).\(^{113}\) Overall, these findings seem to support the interpretation of the results in the EMILIA CNS subgroup analysis termed competing risk, meaning: "the substantial reduction in the incidence of non-CNS recurrences as a first event observed with T-DM1 may be resulting in an increased likelihood of a CNS recurrence as a first event and as the only recurrence."\(^{113}\)
| NCT   | Title                                                                 | Intervention                                      | Eligibility                                                                                                                                                                                                 |
|-------|----------------------------------------------------------------------|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 03994796 | Genomically-guided treatment trial in brain metastases              | Palbociclib or GDC-0084 or entrectinib, dependant on presence of gene mutation | • Clinically actionable alteration in NTRK, ROS1, or CDK or PI3K pathway*<br>• At least one prior HER2 directed therapy in the metastatic setting                                                                 |
| 03190967 | T-DM1 alone vs T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery | Phase I: T-DM1<sup>a</sup> + temozolomide Phase II: randomization T-DM1 + or - temozolomide | • Any number of brain metastases treated with SRS/WBRT within 12 weeks of study entry<br>Phase II: Up to 10 brain metastases treated within 12 weeks of study entry with SRS and/or resection |
| 03417544 | A Phase II study of atezolizumab in combination with pertuzumab plus high-dose trastuzumab for the treatment of central nervous system metastases in patients with HER2-positive breast cancer | Trastuzumab + pertuzumab + atezolizumab          | • At least one measurable CNS metastasis, defined as ≥10 mm in at least one dimension<br>• Untreated CNS lesions in asymptomatic patients<br>• Treated SRS or surgery with untreated and measurable residual areas<br>• Prior WBRT and/or SRS with lesions subsequently progressed are also eligible |
| 03696030 | A Phase 1 cellular immunotherapy study of intraventricularly administered autologous HER2-targeted chimeric antigen receptor (HER2-CAR) T cells in patients with brain and/or leptomeningeal metastases from HER2-positive cancers | HER2-CAR T<sup>c</sup> cells via intraventricular administration | • Recurrent brain metastases after radiation therapy<br>• Recurrent leptomeningeal metastases after intrathecal chemotherapy<br>• Untreated brain or leptomeningeal metastases and refuses to undergo radiation and/or intrathecal chemotherapy<br>• Eligible to enroll in the study and undergo leukapheresis |
| 02442297 | Phase I Study of intracranial injection of T cells expressing HER2-specific chimeric antigen receptors (CAR) in subjects with HER2-positive cancers of the central nervous system (iCAR) | HER2-CAR T cells via intraventricular administration | • HER2-positive solid tumor metastatic to the CNS                                                                                                                                                         |
| 03765983 | Phase II trial of GDC-0084 in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases | Trastuzumab + GDC-0084 (PI3K inhibitor)           | Cohort A:<br>• At least one measurable CNS metastasis, defined as ≥10 mm in at least one dimension<br>• Untreated CNS lesions in asymptomatic patients<br>• Treated SRS or surgery with untreated and measurable residual areas<br>• prior WBRT and/or SRS with lesions subsequently progressed are also eligible<br>Cohort B:<br>• New and/or progressive brain metastasis(es) with clinical indication for resection |
| 01494662 | A Phase II trial of HKI-272 (neratinib), neratinib and capecitabine, and ado-trastuzumab emtansine for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases | Different cohorts receiving: neratinib alone, neratinib + capecitabine, neratinib + T-DM1 | Cohort dependent, either resectable brain metastases or not                                                                                                                                           |
### TABLE 2 (Continued)

| NCT       | Title                                                                 | Intervention                        | Eligibility                                                                 |
|-----------|----------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------|
| 03933982 (Phase II) | Pyrotinib plus vinorelbine in patients with brain metastases from HER2-positive metastatic breast cancer: a prospective, single-arm, open-label study | Pyrotinib + vinorelbine              | • At least one CNS metastases with a longest diameter ≥ 1 cm and            |
|           |                                                                      |                                     | • Controlled CNS symptoms                                                  |
|           |                                                                      |                                     | • No previous WBRT                                                         |
| 03975647 (Phase III) | Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02) | Tucatinib + T-DM1 vs placebo + T-DM1 | Brain metastases patients allowed with:                                   |
|           |                                                                      |                                     | • untreated brain metastases and no need of immediate local therapy        |
|           |                                                                      |                                     | • previously treated brain metastases, either stable or progressing in no need of immediate local therapy |
|           |                                                                      |                                     | • recently treated brain metastases (21 d post WBRT or 28 d after surgical resection) |

4NTRK, neurotrophin receptor tyrosine-kinase; ROS1, ROS proto-oncogene 1; CDK, cyclin dependent kinase; PI3K, phosphatidylinositol-3-kinase.
5T-DM1, ado-trastuzumab emtansine; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy.
6CAR, chimeric antigen receptor.

### 3.2.6 | Trastuzumab deruxtecan (DS8201)

Trastuzumab deruxtecan, initially known as DS-8201, is the second ADC to be FDA approved as third line therapy for metastatic HER2+ BC, based on the impressive results of the phase II DESTINY trial. This ADC is composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor in a 1:8 antibody:cytotoxic ratio. In the DESTINY trial, patients with heavily-pretreated metastatic HER2+ BC with a median of 6 prior lines of therapy all received trastuzumab deruxtecan. The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration to trastuzumab deruxtecan was 14.8 months (95% CI, 13.8 to 16.9), and the median PFS was 16.4 months (95% CI, 12.7 to not reached). Remarkably, PFS for the 24 patients who were enrolled with treated and asymptomatic BrM was 18.1 months (95% CI, 6.7 to 18.1).

Adverse events, grade 3 or higher, were most commonly neutropenia (20.7%), anemia (8.7%), and nausea (7.6%). The drug was also associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%), a toxicity which should be monitored and managed aggressively.

### 4 | RECOMMENDATIONS

#### 4.1 | ASCO guidelines in HER2+ BC BrM

The American Society of Clinical Oncology (ASCO) has published periodic and timely guidelines for management of BrM in patients with HER2+ advanced BC. Those guidelines are expert consensus-based recommendations following a targeted, systematic literature review. The most recent guideline was published in 2018 and had similar recommendations to the previous version, published in 2014. In summary, cases with favorable prognosis and single or limited BrM should receive some combination of surgery and radiation, depending on size, resectability and symptoms. When presenting with diffuse BrM, patients should receive WBRT, and if poor clinical prognosis, palliative care is indicated. If progression of CNS disease following initial radiation therapy occurs, some form of local therapy with radiation and/or surgery should be considered when possible, as well as a clinical trial or best supportive care. Systemic therapy should not be switched if systemic extracranial disease is not progressing. Traditional HER2-targeted therapy algorithms for HER2+ metastatic BC should be offered when systemic disease is progressive.

A suggested algorithm for multidisciplinary management of care for patients with HER2+ BC BrM is presented in Figure 1.

#### 4.2 | Open questions/next steps

Many questions remain to be answered in the management of HER2+ BC BrM around drug delivery, subtype discordance, and the unique biology of BrM. Obtaining active and homogeneous drug penetration into CNS metastatic lesions is only one obstacle to overcome. To complicate matters, discordance between BC subtype markers have also been demonstrated when BrM are compared to primary tumors. Furthermore, whole-exome sequencing of patient-matched BrM and primary tumors demonstrate that metastatic lesions are a product of branched evolution, with mutations “private to the BrM.” Based on these findings and paving the way of precision medicine strategies into BrM management, a phase II clinical trial proposing genomically-guided treatment in BrM was developed (NCT03994796). Patients with histologically proven BrM from any solid tumor, including HER2+ BC, are eligible and will be treated based on specific actionable mutations inherent to the BrM. Patients will be matched to brain permeable therapies based on alterations found in their BrM: CDK alterations to abemaciclib, mTOR/AKT/PI3K alterations to the dual mTOR/PI3K inhibitor, paxalisib/GDC-0084, and NTRK/ROS1 fusions (lung BrM only) to entrectinib. The primary endpoint of this novel clinical trial is overall CNS response rate.
Considering the issues of drug penetration in the CNS and the biologic cascade promoting BrM, preclinical data using a mouse xenograft model of BCBRM demonstrates that temozolomide administered in a preventive fashion can prevent the development of BrM. In these models, temozolomide did not result in reduction in established BrM.\textsuperscript{118} Based on this observation, a phase I/II clinical trial for secondary prevention of BrM in HER2+ BC has been developed, enrolling patients after an initial local therapy to receive T-DM1 with or without temozolomide, with the goal to prevent and decrease incidence of new BrM.\textsuperscript{119} This represents a new study design of “secondary prevention” in BrM clinical trials which could also be utilized in the development of clinical protocols for other subtypes of BCBRM.

As immunotherapy has emerged as one of the most promising ways to approach cancer therapy over the last decade, HER2+ and TNBC are known to be the most immunogenic subtypes of BC. Biomarkers correlated with immunogenicity such as tumor-infiltrating lymphocytes (TIL) levels, PD-L1 expression and tumor mutational burden (TMB) are reportedly more frequent in the HER2+ relative to the luminal subtypes of BC.\textsuperscript{120-122} This observation has led to the development of immunotherapeutic strategies and clinical trials of immunotherapy for advanced HER2+ BC. Though preliminary clinical evidence has shown modest activity of immune checkpoint inhibitors in metastatic HER2+ BC, new strategies and combinations targeting BrM are under evaluation (Table 2). One interesting approach is the use of chimeric antigen receptor-engineered T cells (CART) to target HER2+ BCBRM, demonstrated to be effective with intraventricular delivery of HER2-CAR constructs in xenograft models\textsuperscript{123} and currently being investigated in clinical trials (Table 2).

### 5 CONCLUSIONS

BrM are a frequent clinical challenge for patients with advanced HER2+ breast cancer. The continuous development of newer, brain permeable, anti-HER2 therapeutic options has steadily improved the impact of systemic therapy for patients with metastatic HER2+ breast cancer. In parallel, there has been an increased awareness of BrM as a clinically unmet need for this subtype of breast cancer. The complexity of CNS biology and the unique local microenvironment coupled with the historically limited availability of clinical trials for patients with CNS involvement has contributed to a poorer prognosis for this population in the past. This picture is slowly and steadily changing, in large part due to a paradigm shift resulting in the inclusion of patients with BrM in large, randomized, phase 3 clinical trials such as HER2Climb. Enrollment of patients with BrM in future clinical trials evaluating promising, brain permeable, HER2-targeted therapies should be at the forefront to maintain this forward momentum, with the goal of continuing to improve our patients’ survival and quality of life in a meaningful way.

### ACKNOWLEDGMENTS

The authors thank Translating Duke Health for supporting the Duke Center for Brain and Spine Metastases. We also thank the patients in these studies and their families.

### REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *Ca-Cancer J Clin*. 2020;70(1):7-30.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. *J Clin Oncol*. 2004;22(14):2865-2872.
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. *J Clin Oncol*. 2004;22(17):3608-3617.
4. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous-system metastasis from breast-carcinoma-autopsy study. *Cancers*. 1983;52(12):2349-2354.
5. Arvold ND, Oh KS, Niemierko A, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. *Breast Cancer Res Treat*. 2012;136(1):153-160.
6. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. *J Clin Oncol*. 2010;28(20):3271-3277.
7. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. *Cancers*. 2003;97(12):2972-2977.
8. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. *Br J Cancer*. 2004;91(4):639-643.
9. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. *Clin Cancer Res*. 2009;15(4):1452-1459.
10. Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. *Acta Oncol*. 2006;45(2):196-201.
11. Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22(4):525-531.
12. Pestalozzi BC, Brignoli S, Herceptin(R) (trastuzumab) in cerebrospinal fluid (CSF). Eur J Cancer. 2000;36(suppl 5):S54-S.
13. Stemmler J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol. 2006;24(18):645-S.
14. Patanaphan V, Salazar OM, Risco R. Breast-cancer-metastatic patterns and their prognosis. South Med J. 1988;81(9):1109-1112.
15. Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834-4843.
16. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCTCG N9831. J Clin Oncol. 2014;32(33):3744-3752.
17. Gianni L, Dafni U, Gerber RD, et al. CNS relapses in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol. 2011;12(3):236-244.
18. Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244-248.
19. Mounsey LA, Deal AM, Keith KC, et al. Changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new targeted therapies. Clin Breast Cancer. 2018;18(1):29-37.
20. Nikura N, Hayashi N, Masuda N, et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat. 2014;147(1):103-112.
21. Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancers. 2011;11(8):1602-1611.
22. Vem-Gross T, Lawrence JA, Case LD, et al. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. J Neurooncol. 2012;110(3):381-388.
23. Pegg GL, Ngo D. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Adv Drug Delivery Rev. 2006;58(S-6):723-734.
24. Marsden CG, Wright MJ, Carrier L, Moroz K, Pochampally R, Rowan BG. A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies. BMC Cancer. 2012;12:10.
25. Contreras-Zarate MJ, Ormond DR, Gillen AE, et al. Development of novel patient-derived xenografts from breast cancer brain metastases. Front Oncol. 2017;7:252.
26. Nagpal A, Redvers RP, Ling X, et al. Neoadjuvant nevirapine promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Res. 2019;21(1):94.
27. Gupta P, Srivastava SK. HER2 mediated de novo production of TGFbeta leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer. Mol Oncol. 2014;8(8):1532-1547.
28. Perera M, Ribot EJ, Percy DB, et al. In vivo magnetic resonance imaging for investigating the development and distribution of experimental brain metastases due to breast cancer. Transl Oncol. 2012;5(3):217-225.
29. Palmieri D, Bronder J, Linnell J, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007;67(9):4190-4198.
30. Sirkisoon SR, Carpenter RL, Rikmus T, Miller L, Metheny-Barlow L, Lo HW. EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed). 2016;8:245-263.
31. Da Silva L, Simpson PT, Smart CE, et al. HER2 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res Treat. 2010;12(4):R46.
32. Van Swearingen AED, Siegel MB, Deal AM, et al. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Res Treat. 2018;171(3):637-648.
33. Saunus JM, Quinn MC, Patch AM, et al. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol. 2015;237(3):363-378.
34. Duchnowska R, Sperinde J, Chenna A, et al. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol. 2015;17(9):1241-1249.
35. Priedigkeit N, Hartmaier RJ, Chen Y, et al. Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. 2017;3(5):666-671.
36. Mommy M, Saunus JM, Marturana F, et al. Heregulin-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015;6(6):3932-3946.
37. Zhang S, Huang WC, Zhang L, et al. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res. 2013;73(18):5764-5774.
38. Choy C, Ansari KI, Neman J, et al. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases. Breast Cancer Res. 2017;19(1):51.
39. Contreras-Zarate MJ, Day NL, Ormond DR, et al. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases. Oncogene. 2019;38(24):4685-4699.
40. Sartorius CA, Hanna CT, Gril B, et al. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. 2016;35(22):2881-2892.
41. Zhang L, Sullivan P, Suyama J, Marchetti D. Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer. 2010;8(2):278-290.
42. Sirkisoon SR, Carpenter RL, Rikmus T, et al. TGFU1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. 2020;39(1):64-78.
43. Cordero A, Kanoja D, Miska J, et al. FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis. Oncogene. 2019;38(3):3645-3660.
44. Lyle LT, Lockman PR, Adkins CE, et al. Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2016;22(21):5287-5299.
45. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16(23):5664-5678.
46. Adkins CE, Mohammad AS, Terrell-Hall TB, et al. Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis. 2016;33(4):373-383.
47. Baker JHE, Kyle AH, Reinsberg SA, et al. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment. Clin Exp Metastasis. 2018;35(7):691-705.
48. Lewis Phillips GD, Nishimura MC, Lacap JA, et al. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat. 2017;164(3):581-591.

49. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29(3):770-781.

50. Polli JW, Olson KL, Chisp JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib [N-[3-chloro-4-{[3-fluorobenzoyl]oxy}phenyl]-6-[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine; GW572016]. Drug Metab Dispos. 2009;37(2):439-442.

51. Nakayama A, Takagi S, Yusa T, et al. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse, and rat xenograft tumors, and in an HER2-positive brain metastasis model. J Cancer. 2013;4(7):557-565.

52. Kinoshita M, McDonnell N, Jolesz FA, Hynynen K. Noninvasive localized delivery of herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006;103(31):11719-11723.

53. Arvanitis CD, Askoxylakis V, Guo Y, et al. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc Natl Acad Sci U S A. 2018;115(37):E8717-E8726.

54. Grill B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. JNCI J Nat Cancer Inst. 2008;100(15):1092-1103.

55. Grill B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor microenvironment in brain metastases of HER2-overexpressing tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(10):2758-2768.

56. Tanaka Y, Hirata M, Shinonome S, Torii M, Nezasa KI, Tanaka H. Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2. Cancer Sci. 2014;105(8):1040-1048.

57. Tanaka Y, Hirata M, Shinonome S, Torii M, Nezasa KI, Tanaka H. Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for anti-tumor activity. Sci Rep. 2018;8(1):343.

58. Nounou MI, Adkins CE, Rubinchik E, et al. Anti-cancer antibody trastuzumab-melanotransferrin conjugate (bt2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: an in vivo study. Pharm Res. 2016;33(12):2930-2942.

59. Regina A, Demuele M, Tripathy S, et al. ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther. 2015;14(1):129-140.

60. Grill B, Wei D, Zimmerman AS, et al. A HER2 antibody drug conjugate controls growth of breast cancer brain metastases in heterogeneous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker. Neuro Oncol. 2020.

61. Wan X, Zhong X, Pang X, et al. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain. Oncotarget. 2016;7(23):34038-34051.

62. Wyatt EA, Davis ME. Nanoparticles containing a combination of a drug and an antibody for the treatment of breast cancer brain metastases. Mol Pharmaceutics. 2020;17(2):717-721.

63. Kabraj S, Ni J, Lin NU, Xie S, Winer EP, Zhao JJ. Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain? Clin Cancer Res: Off J Am Assoc Cancer Res. 2018;24(8):1795-1804.

64. Ni J, Ramkisson SH, Xie S, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016;22(7):723-726.

65. Kodack DP, Chung E, Yamashita H, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A. 2012;109(45):E3119-E3127.

66. Kanoja D, Balasnikoviva IV, Mosher RA, et al. Neural stem cells secreting anti-HER2 antibody improve survival in a preclinical model of HER2 overexpressing breast cancer brain metastases. Stem Cells. 2015;33(10):2985-2994.

67. Leoni V, Gatta V, Paladini A, et al. Systemic delivery of HER2-retargeted onconyltic-HSV by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget. 2015;6(33):34774-34787.

68. Priceman SJ, Tilakawardane D, Jeang B, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+ ) breast cancer metastasis to the brain. Clin Cancer Res: Off J Am Assoc Cancer Res. 2018;24(1):95-105.

69. Zafir-Lavie I, Sherbo S, Goltzman H, et al. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases. J Controlled Release. 2018;291:80-89.

70. Rothwell WT, Bell P, Richman LK, et al. Intrathecal viral vector delivery of trastuzumab prevents or inhibits tumor growth of human HER2-positive xenografts in mice. Cancer Res. 2018;78(21):6171-6182.

71. Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013;5(180):180ra48.

72. Vareslija D, Friedigkert N, Fagan A, et al. Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets. J Natl Cancer Inst. 2019;111(4):388-398.

73. Fecci PE, Champion CD, Hoj J, et al. The evolving modern management of brain metastasis. Clin Cancer Res. 2019;25(22):6570-6580.

74. Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastases: an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210-225.

75. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the BRAIN. N Engl J Med. 1990;322(8):494-500.

76. Hatiboglu MA, Wildrick DM, Sawaya R. The role of surgical resection in patients with brain metastases. Cancers. 2017;9(3):387-397.

77. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387-395.

78. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet Oncol. 2004;5(9):597-604.

79. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery plus one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet Oncol. 2004;5(9):597-604.

80. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet Oncol. 2004;5(9):597-604.
82. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65-72.

83. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037-1044.

84. Brown PD, Asher AL, Ballman KV, et al. NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol. 2015;33(15):LBA4.

85. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-1437.

86. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory in patients with metastatic breast cancer treated with targeted therapies. AJNR Am J Neuroradiol. 2009;30(7):1361-1367.

87. Miller JA, Kotecha R, Ahiuwalia MS, et al. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer. 2017;123(12):2283-2293.

88. Boogerd W, Salesio O, Bais EM, Vandersande JJ. Response of BRAIN metastases from breast cancer to systemic chemotherapy. Cancers. 1992;69(4):972-980.

89. Peereboom DM. Chemotherapy in brain metastases. Curr Opin Oncol. 2003;15(2):232-236.

90. Freilich RJ, Seidman AD, Deangelis LM. Central-nervous-system progression of metastatic breast cancer in patients treated with paclitaxel. Cancers. 1995;76(2):232-236.

91. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of BRAIN metastases in breast-carcinoma. Cancers. 1986;58(4):832-839.

92. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol. 2009;14(4):299-306.

93. Morikawa A, Peereboom DM, Thorsheim HR, et al. Capecitabine of BRAIN metastases in breast-carcinoma. Neuro Oncol. 2009;11(2):289-295.

94. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-543.

95. Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081-1089.

96. Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880-888.

97. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for her2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609. https://doi.org/10.1056/NEJMoa1914609.

98. Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated her2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2020;JCO2000775-JCO.JCO2000775. https://doi.org/10.1200/JCO.20.00775.

99. Swain SM, Kim S-B, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461-471.

100. Swain SM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116-1121.

101. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer. N Engl J Med. 2017;377(2):122-131.

102. Martine Piccart MP, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, Guy Jerusalem, Susan Dent, Linda Reaby, Hervé Bonnefoi, Ian Krop, Tsang-Wu Liu, Tadeusz Pierkowsk, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young-Hyuck Im, Ling-Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefania Monturus, Mihaela Sicoc, Sébastien Guillaume, José Bines, Richard Gelber, Giuseppe Viale and Christoph Thomssen, Editor interim overall survival analysis of APHINITY (BIG 4-11): a randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. Paper presented at: San Antonio Breast Cancer Symposium; 2019; San Antonio, TX: Cancer Research; 2020.

103. Torres S, Maralani P, Verma S. Activity of TDM-1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Reports. 2014;2014:br12014205680.

104. Bartsch R, Berghoff AS, Vogl U, et al. Activity of TDM-1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis. 2015;32(7):729-737.

105. Krop IE, Kim S-B, Gonzalez-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689-699.

106. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-1791.

107. Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113-119.

108. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628.
113. Untch M, Geyer CE, Huang C, et al. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). *Ann Oncol*. 2019;30:9.

114. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med*. 2020;382(7):610-621.

115. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update. *J Clin Oncol*. 2018;36(27):2804-2807.

116. Kaidar-Person O, Meattini I, Jain P, et al. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. *Breast Cancer Res Treat*. 2018;167(2):479-483.

117. Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. *Cancer Discov*. 2015;5(11):1164-1177.

118. Palmieri D, Duchnowska R, Woditschka S, et al. Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner. *Clin Cancer Res*. 2014;20(10):2727-2739.

119. Zimmer AS, Steinberg SM, Smart DD, et al. Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. *Future Oncol*. 2020;16:899-909.

120. Luen SJ, Salgado R, Fox S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. *Lancet Oncol*. 2017;18(1):52-62.

121. Kim A, Lee SJ, Kim YK, et al. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. *Sci Rep*. 2017;7(1):11671. https://doi.org/10.1038/s41598-017-11905-7.

122. Thomas A, Routh ED, Pullikuth A, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. *Onco Targets Ther*. 2018;7(1):e1490854. https://doi.org/10.1080/2162402X.2018.1490854.

How to cite this article: Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: A new and exciting landscape. *Cancer Reports*. 2022;5:e1274. https://doi.org/10.1002/cnr2.1274